X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.12−0.05 (-1.58%)
Close on Nov 13, 2026Market cap $309.34MP/E –Yield –
X4 Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
X4 Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 68.8%. For fiscal 2025 it was 11.4%, against 69.3% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.4% | −57.9 |
| FY2024 | Dec 31, 2024 | 69.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 81.7% | +3.6 |
| Q2 FY2026 | Jun 30, 2026 | 32.6% | −48.2 |
| Q1 FY2026 | Mar 31, 2026 | 76.1% | +500.1 |
| Q4 FY2025 | Dec 31, 2025 | 83.5% | +3.6 |
| Q3 FY2025 | Sep 30, 2025 | 78.1% | +18.6 |
| Q2 FY2025 | Jun 30, 2025 | 80.8% | +28.4 |
| Q1 FY2025 | Mar 31, 2025 | -424.0% | – |
| Q4 FY2024 | Dec 31, 2024 | 79.9% | – |
| Q3 FY2024 | Sep 30, 2024 | 59.5% | – |
| Q2 FY2024 | Jun 30, 2024 | 52.4% | – |
See a number that looks wrong?